Valuation: AstraZeneca PLC

Market Cap 254B 218B 204B 187B 351B 24,308B 357B 2,404B 941B 12,191B 955B 934B 40,309B P/E 2026 *
21x
P/E 2027 * 18.3x
Enterprise Value 274B 235B 219B 201B 378B 26,156B 384B 2,586B 1,013B 13,118B 1,027B 1,005B 43,372B EV / Sales 2026 *
4.33x
EV / Sales 2027 * 3.98x
Free-Float
96.63%
Yield 2026 *
2.03%
Yield 2027 * 2.15%
1 day-13.39%
Current year+1.81%
Current year 152.4
Extreme 152.4
166.3
1 year 124.15
Extreme 124.15
166.3
3 years 111
Extreme 111
166.3
5 years 94.29
Extreme 94.29
166.3
10 years 47.72
Extreme 47.715
166.3
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
-13.88%0.00% - - 254B
-1.50%+4.34%+78.83%+129.35% 1,141B
-1.28%+3.59%+51.80%+62.22% 659B
-0.92%+5.89%+26.99%+76.87% 470B
0.00%+2.15%+41.04%+45.54% 366B
-1.49%+2.20%+23.54%+40.51% 302B
-1.61%+2.31%+0.02%+12.22% 254B
-2.16%+4.30%+47.01%+67.17% 239B
-1.08%-0.08%-13.77%-52.74% 207B
-2.47%+5.11%+22.29%+91.20% 183B
Average -2.48%+4.10%+30.86%+52.48% 424.55B
Weighted average by Cap. -1.98%+4.31%+44.85%+72.91%

Financials

2026 *2027 *
Net sales 63.25B 54.25B 50.66B 46.48B 87.4B 6,045B 88.84B 598B 234B 3,032B 237B 232B 10,025B 66.84B 57.33B 53.54B 49.12B 92.37B 6,388B 93.89B 632B 247B 3,204B 251B 246B 10,594B
Net income 12.07B 10.35B 9.67B 8.87B 16.68B 1,154B 16.95B 114B 44.67B 579B 45.32B 44.33B 1,913B 13.72B 11.77B 10.99B 10.08B 18.95B 1,311B 19.27B 130B 50.76B 657B 51.5B 50.38B 2,174B
Net Debt 19.33B 16.58B 15.48B 14.2B 26.71B 1,847B 27.15B 183B 71.53B 926B 72.57B 70.99B 3,063B 11.65B 10B 9.33B 8.56B 16.1B 1,114B 16.37B 110B 43.12B 559B 43.75B 42.8B 1,847B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
163.97USD
Average target price
212.30USD
Spread / Average Target
+29.47%

Quarterly revenue - Rate of surprise